Efficacy of Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer

Jin Tae Jung

doi:10.4166/kjg.2016.68.5.234

Journal List > Korean J Gastroenterol > v.68(5) > 1007574

Go to TopGo to Top Go to BottomGo to Bottom

TOOLS

Jung: Efficacy of Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer

Editorial

Korean J Gastroenterol 2016;68(5):234-236.

Published online: 4 October 2016

DOI: https://doi.org/10.4166/kjg.2016.68.5.234

Efficacy of Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer

Jin Tae Jung

Department of Internal Medicine, Catholic University of Daegu School of Medicine, Daegu, Korea

Correspondence to: Jin Tae Jung, Department of Internal Medicine, Catholic University of Daegu School of Medicine, 33 Duryugongwon-ro 17-gil, Nam-gu, Daegu 42472, Korea. Tel: +82-53-650-4217, Fax: +82-53-624-3281, E-mail: jungjt@cu.ac.kr

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Article

Clinical Outcome of Doublet and Triplet Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer

References

1. Cancer inspected through statistics. [Internet]. Goyang: National Cancer Information Center;2013. [cited 2016 Nov 9]. Available from:. http://www.cancer.go.kr/mbs/cancer/sub-view.jsp?id=cancer_040101000000.

2. Hartgrink HH, van de Velde CJ, Putter H, et al. Neoadjuvant chemotherapy for operable gastric cancer: long term results of the Dutch randomised FAMTX trial. Eur J Surg Oncol. 2004; 30:643–649.

3. Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006; 355:11–20.

4. Schuhmacher C, Gretschel S, Lordick F, et al. Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954. J Clin Oncol. 2010; 28:5210–5218.

5. Ychou M, Boige V, Pignon JP, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol. 2011; 29:1715–1721.

6. Sym SJ, Chang HM, Ryu MH, et al. Neoadjuvant docetaxel, capecitabine and cisplatin (DXP) in patients with unresectable locally advanced or metastatic gastric cancer. Ann Surg Oncol. 2010; 17:1024–1032.

7. Park I, Ryu MH, Choi YH, et al. A phase II study of neoadjuvant docetaxel, oxaliplatin, and S-1 (DOS) chemotherapy followed by surgery and adjuvant S-1 chemotherapy in potentially resectable gastric or gastroesophageal junction adenocarcinoma. Cancer Chemother Pharmacol. 2013; 72:815–823.

8. Jiang L, Yang KH, Guan QL, Chen Y, Zhao P, Tian JH. Survival benefit of neoadjuvant chemotherapy for resectable cancer of the gastric and gastroesophageal junction: a metaanalysis. J Clin Gastroenterol. 2015; 49:387–394.

9. Kim JS, Kang SH, Moon HS, Sung JK, Jeong HY, Sul JY. Clinical outcome of doublet and triplet neoadjuvant chemotherapy for locally advanced gastric cancer. Korean J Gastroenterol. 2016; 68:245–252.

TOOLS

Similar articles